• Return to Headlines

Synta Pharmaceuticals Leads the Companies in the Biotechnology Industry Offering Investors Top Value (SNTA, LUNA, FOLD, AFFY, GTXI)

Written on Fri, 07/02/2010 - 3:11am
By Chip Brian

Below are the top five companies in the Biotechnology industry as measured by the price to sales per share ratio. Often companies with the lowest ratio present the greatest value to investors.
Synta Pharmaceuticals (NASDAQ:SNTA) has a price/sales ratio of 0.61x based on a current price of $2.59 and trailing 12-month sales per share of $4.23.
Luna Innovations (NASDAQ:LUNA) has a price/sales ratio of 0.73x based on a current price of $2.16 and trailing 12-month sales per share of $2.95.
Amicus Therapeutics (NASDAQ:FOLD) has a price/sales ratio of 0.83x based on a current price of $2.2 and trailing 12-month sales per share of $2.64.
Affymax (NASDAQ:AFFY) has a price/sales ratio of 0.92x based on a current price of $5.52 and trailing 12-month sales per share of $5.97.
GTx (NASDAQ:GTXI) has a price/sales ratio of 1.57x based on a current price of $2.91 and trailing 12-month sales per share of $1.86.
SmarTrend is bearish on shares of FOLD and our subscribers were alerted to Sell on September 30, 2009 at $8.98. The stock has fallen 75.5% since the alert was issued.

Keywords: synta pharmaceuticals price to sales ratio

Ticker(s): SNTA LUNA FOLD AFFY GTXI

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.